Richard Sternberg, DO
Pulmonary Disease · Hamilton, OHNPI 1356333470
Payments from drug & device makers
Across 434 payments — averaging $76.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$23K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Grifols USA, LLC$700
- Amgen$547
- plus $4K from 30 others
What the payments were for
- Consulting fees$3,20010%
- Speaking & faculty fees$18,10054%
- Travel & lodging$8483%
- Food & beverage$11,02033%
- Education$1741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 56 | $23,313 |
| AstraZeneca | 57 | $2,124 |
| GSK | 86 | $1,431 |
| Regeneron Healthcare Solutions, Inc. | 34 | $1,326 |
| Grifols USA, LLC | 29 | $700 |
| Amgen | 16 | $547 |
| Mylan Specialty L.p. | 22 | $546 |
| Sanofi | 22 | $424 |
| United Therapeutics Corporation | 15 | $361 |
| Jazz Pharmaceuticals Inc. | 5 | $226 |
| Johnson & Johnson | 2 | $225 |
| Inogen, Inc. | 14 | $198 |
| Sunovion Pharmaceuticals Inc. | 7 | $180 |
| Pulmonx Corporation | 5 | $171 |
| Actelion Pharmaceuticals US, Inc. | 10 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $141 |
| Noah Medical Corporation | 1 | $134 |
| Janssen Scientific Affairs, LLC | 1 | $130 |
| Amarin Pharma, Inc. | 1 | $116 |
| Insmed, Inc. | 4 | $114 |
| Genentech USA, Inc. | 5 | $109 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Viatris Specialty LLC | 4 | $86 |
| Electromed, Inc. | 5 | $71 |
| Philips North America LLC | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Merck | 3 | $53 |
| Novartis | 3 | $47 |
| Mayne Pharma Commercial LLC | 2 | $37 |
| Pfizer | 2 | $34 |
| Covis Pharma GmbH | 2 | $32 |
| Gilead | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,341 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 50 | $212,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $145,050 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $144,223 |
| Dupixent SyringeDupilumab | 26 | $106,881 |
| XolairOmalizumab | 17 | $98,441 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $96,005 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $74,258 |
| Spiriva RespimatTiotropium Bromide | 93 | $69,707 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $20,882 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $10,838 |
| Spiriva HandihalerTiotropium Bromide | 14 | $10,071 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,758 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 280 | $8,734 |
| EliquisApixaban | 14 | $8,332 |
| Atrovent HfaIpratropium Bromide | 11 | $5,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,431 | $272,775336 claims |
| Grifols USA, LLCProlastin C | $700 | $144,22313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,124 | $83,016124 claims |
| Boehringer IngelheimSpiriva Respimat | $23,313 | $69,70793 claims |
| PfizerEliquis | $34 | $8,33214 claims |
| MerckDulera | $53 | $5,19514 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $56 | $1,38234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Hamilton
- David DinuoscioHamilton$91K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.